Metformin is the first-line therapy for the treatment of individuals with type 2 diabetes, yet its precise mechanism of action remains unclear. Ma and colleagues now identify a membrane protein PEN2 as a novel target of metformin at low concentrations which specifically activates lysosomal AMP-activated protein kinase (AMPK) via AMP-independent mechanism, leading to therapeutic benefits.